Agendia Joins the Personalized Medicine Coalition
Complete the form below to unlock access to ALL audio articles.
Agendia BV. announces that it has joined the US-based Personalized Medicine Coalition (PMC).
"The PMC is playing a key role in shaping the US public policy on personalized medicine. We are very pleased to be a member of a group that will dramatically impact the treatment of patients in the future.
After we got both our first IVDMIA product, MammaPrint®, as well as our logistical sampling and shipping procedure, RNARetain®, cleared by the FDA we believe it is now time to actively participate in the discussion about the implementation of personalized medicine in the US", said Dr. Bernhard Sixt, CEO of Agendia BV.
Edward Abrahams, Executive Director of the PMC, welcomed the addition of the Netherlands-based personalized medicine company: "We very much look forward to Agendia's involvement in PMC's activities, in particular its participation in our efforts to shape an appropriate regulatory pathway for personalized medicine products."
